Announcing Spiderwort’s CelluBridge Clinical Advisory Board 
Pioneers in Neuroscience Join Forces with Spiderwort to Revolutionize Spinal Cord Injury Treatment
Ottawa, Canada — October 9, 2024 — Spiderwort Inc., the biotechnology company innovating in cellulose-based tissue engineering, today announced its Clinical Advisory Board for CelluBridge, the firm’s proprietary medical device.
Comprising distinguished experts from the fields of neurosurgery and neurology, the Clinical Advisory Board is positioned to deliver invaluable strategic guidance and clinical insights. This announcement marks a significant milestone as Spiderwort ushers in a new era of innovation and transformative research in spinal cord therapies. The Clinical Advisory Board is made up of five leaders across the US and Canada:
- Dr. James Harrop, MD, FACS, MHSQS: A reputed neurosurgeon based at Thomas Jefferson University in Philadelphia, PA. Dr. Harrop’s career has seen significant advancements in spinal cord treatments. Dr. Harrop is the Neurologic director of the Delaware Valley SCI (spinal cord injury) centre and spearheaded the creation of Thomas Jefferson University’s Comprehensive Spine Unit.
- Dr. Eve Tsai, MD, PhD, FRCSC, CIP: Dr. Tsai operates from and is the Suruchi Bhargava Chair in Spinal Cord and Brain Regeneration at the Ottawa Hospital. Dr Tsai’s practice focuses on various spine and spinal cord diseases, including spinal cord injury, spinal tumors, syringomyelia, and myelopathy. Dr. Tsai is a recipient of numerous clinical, research, teaching, and humanitarian awards and contributions to neurosurgery have garnered international acclaim.
- Dr. Keith Tansey, MD, PhD, FASNR, FASIA: As a professor at the University of Mississippi Medical Center and a physician scientist at the Jackson VA Medical Center, Dr. Tansey brings deep knowledge of spinal cord injuries and neuro-regenerative therapies. Dr. Tansey is a fellow and past-president of the American Spinal Injury Association and has served on the boards of the American Society for Neurorehabilitation and the International Society for Restorative Neurology.
- Dr. Rajiv Saigal, MD, PhD, FAANS: An Associate Professor of neurological surgery and Director of SCI Clinical Trials at UCSF. His expertise is in spinal cord injury and neurotrauma. He has a PhD in medical engineering and has published on engineering and clinical techniques for improving care for SCI patients. Dr. Saigal co-chairs the North American Spine Society Section on SCI and is a prior Vice Chair of the American Spinal Injury Association Program Committee.
- Martin Codyre, BEng, MScL: An engineer, neuroscientist, and entrepreneur with a deeply personal commitment to advancing therapies for spinal cord injury. After sustaining a complete C6 injury, Martin redirected his career to become a neuroscientist and a driving force in the pursuit of treatments for spinal cord injuries. His expertise lies in neural repair, specifically in spinal cord injury, and he has spent over a decade contributing to the development of therapeutics in this field. Well-respected within the SCI community, Martin is a member of ASIA, ISCOS, SFN, and MIEI, with unique insights into leading research areas and laboratories worldwide. He combines this with a comprehensive understanding of clinical translation and the biotechnology industry, positioning himself at the intersection of research and patient advocacy.
“Assembling this acclaimed team is a significant step forward for Spiderwort,” said Dr. Charles M. Cuerrier, CEO and Co-founder of Spiderwort, “The insights and expertise from our Clinical Advisory Board ensures CelluBridge stays at the cutting edge of regenerative medicine advancements.”
About Spiderwort
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort’s biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Media Contact
Shannon Murphy
s.murphy@spiderwortbio.com
613-808-5939